Drug intelligence / Profile preview

tenofovir alafenamide + lamivudine

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

Tenofovir alafenamide + lamivudine is a combination of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) used for the treatment of HIV-1 infection. Tenofovir alafenamide is a prodrug of tenofovir with enhanced plasma stability and more efficient delivery to target cells compared to tenofovir disoproxil fumarate. Lamivudine is a nucleoside reverse transcriptase inhibitor. Both drugs work by inhibiting HIV viral replication through competitive inhibition of viral reverse transcriptase and incorporation into viral DNA, causing chain termination.

Targets

Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)

Beyond the preview

Go deeper on tenofovir alafenamide + lamivudine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenofovir alafenamide + lamivudine.

Explore the full profile